Lerner Vladimir, McCaffery Peter J A, Ritsner Michael S
Faculty of Health Sciences, Be'er Sheva Mental Health Center, Ben-Gurion University of the Negev, Beersheba, Israel.
Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK.
CNS Drugs. 2016 Apr;30(4):269-80. doi: 10.1007/s40263-016-0316-9.
This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.
本综述阐述了将类视黄醇受体作为治疗精神分裂症和分裂情感性障碍的靶点的基本原理，并报告了迄今为止在这方面取得的进展，以及视黄酸在正常大脑功能和精神状态中的作用。在简要介绍之后，我们描述了视黄酸在大脑中的正常功能。接着，我们研究了精神分裂症中类视黄醇失调的证据。最后，讨论了两项使用类视黄醇（贝沙罗汀）进行的附加临床试验的结果。本综述的作者认为，靶向类视黄醇受体可能是治疗精神分裂症和分裂情感性障碍的一种新方法。有必要进行进一步的研究。
